Syntehsis and evaluation of Gd3+ -Trp-PLGA as novel nanosized MR tumor imaging candidate

Document Type : Research Paper


1 Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Pharmaceutics & Medical Nanotechnology, Branch of Pharmaceutical Sciences, Islamic Azad University, Tehran, Iran

3 Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

4 Quality Control Department, Pasteur Institute of Iran

5 Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

6 Iran ministry of health and medical education, deputy ministry for education,Tehran , Iran


Objective(s): Early detection of cancer can significantly increase the likelihood of successful treatment, and imaging assay can have a significant impact on cancer diagnosis. Although gadolinium compounds are used as a contrast agent in MRI, this substance has side effects and disadvantages. Nanotechnology has so far had a significan impact on medical imaging methods, especially MRI, nanoparticles are contrast enhancers that Each with its characteristics have increased the quality of images and reduced toxicity.
Materials and Methods: In this study, a novel nano-conjugate based PLGA-tryptophan was synthesized and loaded with Gd3+ for using it as a potential MR imaging contrast agent to overcome the previous disadvantage. In vitro cell toxicity, cellular uptake and MR imaging parameters of the prepared nanoconjugate were investigated ,
Results: The results showed no in vivo toxicity plus flowcytometry assays, good cellular uptake and large longitudinal (r1).
Conclusion: Convenient features of the nano-probe indicate that it is a promising agent to use as a MR imaging agent.


1.Ma X, Yu H. Cancer issue: global burden of cancer. YJBM. 2006; 79(3-4): 85.
2.Barreto JA, O’Malley W, Kubeil M, Graham B, Stephan H, Spiccia L. Nanomaterials: applications in cancer imaging and therapy. Adv Mater. 2011; 23(12): H18-H40.
3.Salata OV. Applications of nanoparticles in biology and medicine. J Nanobiotechnol. 2004; 2(1): 3.
4.Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer. 2006; 6(9): 688-701.
5.Doiron AL, Homan KA, Emelianov S, Brannon-Peppas L. Poly (lactic-co-glycolic) acid as a carrier for imaging contrast agents. Pharm Res. 2009; 26(3): 674-682.
6.Mariano RNs, Alberti D, Cutrin JC, Geninatti Crich S, Aime S. Design of PLGA based nanoparticles for imaging guided applications. Mol Pharm. 2014; 11(11): 4100-4106.
7.Liu J, Xu J, Zhou J, Zhang Y, Guo D, Wang Z. Fe3O4-based PLGA nanoparticles as MR contrast agents for the detection of thrombosis. Int J Nanomedicine. 2017; 12: 1113.
8.Schleich N, Sibret P, Danhier P, Ucakar B, Laurent S, Muller RN. Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. Int J Pharm. 2013; 447(1-2): 94-101.
9.del Amo EM, Urtti A, Yliperttula M. Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci. 2008; 35(3): 161-174.
10.Peng T, Liu K, Gao L, Gao L, Chen J, Wang J. Poly (l-γ-glutamylglutamine) Polymer Enhances Doxorubicin Accumulation in Multidrug Resistant Breast Cancer Cells. Molecules. 2016 ;21(6): 720.
11.Ali I, Wani WA, Haque A, Saleem K. Glutamic acid and its derivatives: candidates for rational design of anticancer drugs. Future Med Chem. 2013; 5(8): 961-978.
12.Khosroshahi A, Amanlou M, Sabzevari O, Daha F, Aghasadeghi M, Ghorbani M. A comparative study of two novel nanosized radiolabeled analogues of methionine for SPECT tumor imaging. Curr Med Chem. 2013; 20(1): 123-133.
13.Ananieva E. Targeting amino acid metabolism in cancer growth and anti-tumor immune response. World J Biol Chem. 2015; 6(4): 281.
14.Schaechter JD, Wurtman RJ. Serotonin release varies with brain tryptophan levels. Brain Res. 1990; 532(1-2): 203-210.
15.Ikeda M, Tsuji H, Nakamura S, Ichiyama A, Nishizuka Y, Hayaishi O. Studies on the biosynthesis of nicotinamide adenine dinucleotide II. a role of picolinic carboxylase in the biosynthesis of nicotinamide adenine dinucleotide from tryptophan in mammals. J Biol Chem. 1965; 240(3): 1395-401.
16.Palme K, Nagy F. A new gene for auxin synthesis. Cell. 2008;133(1): 31-32.
17.Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine. 2011; 6: 877.
18.Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012; 161(2): 505-522.
19.Locatelli E, Franchini MC. Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system. J Nanoparticle Res. 2012; 14(12): 1316.
20.Bala I, Hariharan S, Kumar MR. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug. 2004; 21(5).
21.Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011; 3(3): 1377-1397.
22.Tabatabaei Mirakabad FS, Nejati-Koshki K, Akbarzadeh A, Yamchi MR, Milani M, Zarghami N, et al. PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev. 2014; 15(2): 517-535.
23.Hazari PP, Shukla G, Goel V, Chuttani K, Kumar N, Sharma R, et al. Synthesis of specific SPECT-radiopharmaceutical for tumor imaging based on methionine: 99mTc-DTPA-bis (methionine). Bioconjug Chem. 2010;21(2): 229-239.
24.Sinha D, Shukla G, Chuttani K, Chandra H, Mishra AK. Synthesis and biological evaluation of 99mTc-DTPA-bis (His) as a potential probe for tumor imaging with SPECT. Cancer Biother Radiopharm. 2009; 24(5): 615-620.
25.Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010; 35(8): 427-433.
26.Palego L, Betti L, Rossi A, Giannaccini G. Tryptophan Biochemistry: Structural, Nutritional, Metabolic, and Medical Aspects in Humans. J Amino Acids. 2016; 2016: 8952520.